Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Antiplatelet therapy in children: why so different from adults'?

Bassareo PP, Fanos V, Iacovidou N, Mercuro G.

Curr Pharm Des. 2012;18(21):3019-33. Review.

PMID:
22564296
2.

Antiplatelet drugs. A comparative review.

Schrör K.

Drugs. 1995 Jul;50(1):7-28. Review.

PMID:
7588091
3.

Update on aspirin in the treatment and prevention of cardiovascular disease.

Hennekens CH.

Am J Manag Care. 2002 Dec;8(22 Suppl):S691-700. Review.

4.

Antiplatelet therapy in children.

Israels SJ, Michelson AD.

Thromb Res. 2006;118(1):75-83. Epub 2005 Feb 1. Review.

PMID:
16709476
5.

Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.

Biller J.

J Neurol Sci. 2009 Sep 15;284(1-2):1-9. doi: 10.1016/j.jns.2009.04.001. Epub 2009 Apr 19. Review.

PMID:
19380153
6.

Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.

Reaume KT, Regal RE, Dorsch MP.

Ann Pharmacother. 2008 Apr;42(4):550-7. doi: 10.1345/aph.1K433. Epub 2008 Mar 4. Review.

PMID:
18319394
7.

Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.

Mousa SA, Bozarth JM, Forsythe MS, Jackson SM, Leamy A, Diemer MM, Kapil RP, Knabb RM, Mayo MC, Pierce SK, et al.

Circulation. 1994 Jan;89(1):3-12.

PMID:
8281661
8.

Safety of fixed-dose aspirin-extended-release dipyridamole in patients with ischemic heart disease.

Crown N, Mysak T.

Am J Health Syst Pharm. 2010 May 1;67(9):728-33. doi: 10.2146/ajhp080645. Review.

PMID:
20410547
9.

Antiplatelet agents and randomized trials.

Diener HC.

Rev Neurol Dis. 2007 Fall;4(4):177-83. Review.

PMID:
18195669
10.

Newer antiplatelet therapies in stroke prevention.

Davis SM, Donnan GA.

Aust Fam Physician. 2001 Feb;30(2):129-34.

PMID:
11280112
11.

Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?

Diener HC.

Int J Stroke. 2006 Feb;1(1):4-8. doi: 10.1111/j.1747-4949.2005.00016.x.

PMID:
18706062
12.

Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].

Kirshner HS.

Int J Clin Pract. 2007 Oct;61(10):1739-48. Review. Erratum in: Int J Clin Pract. 2007 Nov;61(11):1957.

13.

Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke.

Lenz T, Wilson A.

Clin Pharmacokinet. 2003;42(10):909-20. Review.

PMID:
12885264
14.

Aggrenox: a combination of antiplatelet drugs for stroke prevention.

[No authors listed]

Med Lett Drugs Ther. 2000 Feb 7;42(1071):11-2. No abstract available.

PMID:
10725967
15.

Primary and secondary stroke prevention with antiplatelet drugs.

Diener HC.

Curr Pharm Des. 2006;12(10):1293-7. Review.

PMID:
16611114
16.

Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.

Guthrie R.

Adv Ther. 2011 Jun;28(6):473-82. doi: 10.1007/s12325-011-0026-0. Epub 2011 May 3. Review.

PMID:
21547541
17.

Prevention of ischaemic stroke--antiplatelets.

McCabe DJ, Brown MM.

Br Med Bull. 2000;56(2):510-25. Review.

PMID:
11092100
18.

Antiplatelet therapy for stroke prevention.

Hankey GJ.

Curr Atheroscler Rep. 2007 Oct;9(4):312-8. Review.

PMID:
18173959
19.

Combination antiplatelet agents for secondary prevention of ischemic stroke.

Vande Griend JP, Saseen JJ.

Pharmacotherapy. 2008 Oct;28(10):1233-42. doi: 10.1592/phco.28.10.1233. Review.

PMID:
18823219
20.

Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.

Spinler SA.

Pharmacotherapy. 2009 Jul;29(7):812-21. doi: 10.1592/phco.29.7.812. Review.

PMID:
19558255

Supplemental Content

Support Center